Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, Fulcrum Therapeutics Collaborate on Target Discovery Using CRISPR Screens

NEW YORK (GenomeWeb) – The UK's Horizon Discovery Group and Fulcrum Therapeutics have announced a collaboration to use CRISPR/Cas9-based screening to identify drug targets in genetic diseases.

Under the terms of the agreement, Cambridge, Massachusetts-based Fulcrum will use Horizon's CRISPR screening platform to find targets for regulating gene expression in diseases with no current treatment options. The collaboration will last approximately six months and will be done under a full-time equivalent plus consumables model.

Financial and other terms of the agreement were not disclosed.

"CRISPR-based screening promises to be a powerful tool for the identification of novel targets and the collaboration with Fulcrum demonstrates the potential for this technology to be used in areas outside of oncology," Horizon CEO Darrin Disley said in a statement. "This partnership confirms Horizon's role as a preferred partner not only for established biotechnology and pharmaceutical companies, but also for startups looking for long-term collaborations rather than having to build in-house capabilities."

Last week, Horizon announced a partnership with Roche subsidiary Ventana Medical Systems to create reference standards for immunohistochemistry in cancer diagnostics.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.